Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG004A versus placebo with best supportive care in advanced pancreatic cancer
CTR20253026Phase 3Active
- Sponsor
- Hangzhou Miracogen
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of MRG004A in pancreatic cancer (PC), sponsored by Hangzhou Miracogen. Started Jan 2026; status: active.
02
Drugs
MRG004A
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20253026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253026.